The Medical Letter on Drugs and Therapeutics
Bexsero - A Second Serogroup B Meningococcal Vaccine
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved Bexsero (Novartis/GSK), a vaccine that protects against invasive meningococcal disease caused by Neisseria meningitidis serogroup B. It is the second serogroup B meningococcal vaccine to be approved in the US; Trumenba was the first.1 Both vaccines are approved for use in persons 10-25 years old. Bexsero is approved in Europe, Canada, and Australia for use in children as young as 2 months old.

SEROGROUP B MENINGOCOCCAL DISEASE — Five major serogroups (A, B, C, Y, and W) of N. meningitidis cause most invasive meningococcal disease worldwide. In the US, serogroup B causes about 60% of all meningococcal disease in children <5 years old and about 50% of cases in young adults 17-22 years old.2 Until the approval of Trumenba last year, no vaccine was licensed in the US ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Bexsero - A Second Serogroup B Meningococcal Vaccine
Article code: 1482b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian